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Abstract
The generation of induced pluripotent stem cells (iPSCs), especially the generation of
patient-derived pluripotent stem cells (PSCs) suitable for disease modelling in vitro,
opens the door for the potential translation of stem-cell related studies into the clinic.
Successful replacement, or augmentation, of the function of damaged cells by patient-
derived differentiated stem cells would provide a novel cell-based therapy for skeletal
muscle-related diseases. Since iPSCs resemble human embryonic stem cells (hESCs) in
their ability to generate cells of the three germ layers, patient-specific iPSCs offer
definitive solutions for the ethical and histo-incompatibility issues related to hESCs.
Indeed human iPSC (hiPSC)-based autologous transplantation is heralded as the future
of regenerative medicine. Interestingly, during the last years intense research has been
published on disease-specific  hiPSCs derivation and differentiation into relevant
tissues/organs providing a unique scenario for modelling disease progression, to screen
patient-specific  drugs  and  enabling  immunosupression-free  cell  replacement
therapies. Here, we revise the most relevant findings in skeletal muscle differentia‐
tion using mouse and human PSCs. Finally and in an effort to bring iPSC technology
to the daily routine of the laboratory, we provide two different protocols for the
generation of patient-derived iPSCs.
Keywords: Pluripotent stem cells, Myogenic differentiation, Disease modelling, Pa‐
tient-specific induced pluripotent stem cells, Muscular dystrophy
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1. Introduction
Regenerative Medicine aims to restore the loss of function in tissues and organs due to any
cause (trauma, stress, aging, or disease) by the replacement of dysfunctional structures with
competent cells, tissues, or organs. In order to achieve this goal Regenerative Medicine takes
advantage of different forefront methodologies, such the use of stem cells, gene therapy, and
tissue engineering among others.
1.1. Human embryonic stem cells (hESCs)
The isolation and derivation of hESCs by Thompson and colleagues in 1998 attracted signifi‐
cant attention in the Regenerative Medicine field [1]. Indeed, regenerative cell transplantation
therapies have been expected to treat incurable diseases, such as spinal cord injury [2],
neurodegenerative disease [3], heart failure [4,5], diabetes [6], and retinal disease [7].
Nowadays, clinical application of hESCs still shows many concerns regarding the use of
human embryos, tissue rejection after transplantation, and tumour formation. However,
hESCs possess the dual ability to proliferate indefinitely without phenotypic alterations, and
more importantly, to differentiate, theoretically, into all cell types in the human body. These
qualities suggest extensive utility of hESCs in applications varying from the definition of
differentiation protocols, to the generation of drug screening platforms for disease treatment.
Thus, hESCs represent an ideal source for understanding skeletal muscle development and
disease, such skeletal muscle.
1.2. Induced pluripotent stem cells (iPSCs)
In 2006 Professor Shinya Yamanaka and colleagues [8] showed for the very first time, that by
introducing different transcription factors the epigenetic status of somatic cells could be
reverted to pluripotency. In particular, the Japanese team ectopically induced the expression
of specific transcription factors related with embryonic stem cells (ESCs) biology, generating
in a period of only 30 days, cells that were identical to mouse ESCs (mESCs) in terms of self-
renewal capacity, expression of endogenous pluripotency-related factors, and in vivo and in
vitro differentiation potential to give rise to cells belonging to the three germ layers of the
embryo (ectoderm, mesoderm, endoderm). This discovery was awarded with the Nobel Price
of Medicine in 2012 to Professor Shinya Yamanaka.
While, at first, somatic reprogramming was described using mouse embryonic fibroblasts, the
Japanese team could show that also a reduced formula of the original “Yamanaka cocktail”
could be used to reprogram human somatic cells towards human iPSCs (hiPSCs) [9]. Since
2007 different research groups, including us, have shown that iPSC technology can be applied
to reprogram a huge variety of human somatic cells, independently of their embryonic origin
[10–13]. Interestingly, during the last years the generation of protocols avoiding the use of
lentiviral or retroviral vectors for the expression of Yamanaka factors has involved the
definition of novel strategies for hiPSCs generation, including the use of recombinant proteins
[14,15], episomal vectors [16], or mRNAs [17,18], among others [13]. Thus, the generation of
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hiPSCs, especially the generation of patient-derived iPSCs suitable for disease modelling in
vitro, opens the door for the potential translation of patient-derived iPSCs into the clinic.
Successful replacement or augmentation of the function of damaged cells by patient-derived
differentiated stem cells would provide a novel cell-based therapy for skeletal muscle-related
diseases.
Satellite cells (SCs), the adult stem cell pool in skeletal muscle, are often compromised in
patients with muscle dystrophies (MDs). Over the last decades the understanding of the
transcription factors and intrinsic and extrinsic signals that govern SCs or terminally differ‐
entiated myogenic cells have represented a good starting point for the definition of protocols
for the generation of myogenic cells from PSCs (both from mouse and human ESCs and iPSCs).
In the same manner, the generation of patient-derived cell platforms can help us to develop
experimental strategies toward generating muscle stem cells, either by differentiating patient-
specific iPSCs or by converting patient’s somatic cells towards myogenic cells (transdifferen‐
tiation). Overall, the possibility to generate disease-free patient iPSCs can help us to identify
which are the mechanisms driving muscle disease, and more importantly, to develop new
compounds for treating MDs (Figure 1).
Figure 1. Patient iPSCs represent an unprecedented tool for the generation of in vitro platforms for disease modelling
and the definition of protocols for PSCs differentiation. The correction of the genetic defect(s) leading to disease may
help to understand the molecular and cellular mechanisms driving disease gestation and progression, and more im‐
portantly, to identify novel mechanisms leading to muscle regeneration.
2. General approaches to induce in vitro differentiation of pluripotent stem
cells (PSCs)
Both mouse and human PSCs are routinely cultivated in the presence of feeder layers. PSCs
grow on the feeder layers as colonies (Figure 2). Generally, human and mouse PSCs are
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enzymatically dissociated with trypsin, acutase, or dispase to obtain a suspension of single
cells, which is then transferred for subculture and expansion or differentiation purposes. For
mouse PSCs, LIF can substitute for feeder layers. However, since LIF is not effective for human
PSCs, in the last years different chemically defined media have been generated in order to
sustain human PSCs culture and expansion in feeder-free substrates.
Figure 2. PSCs are typically maintained in mitotically inactivated supportive cells. A) Mouse iPSCs cultured on top of
irradiated mouse embryonic fibroblasts grow in tight colonies that are further trypsinized for subculture or differentia‐
tion purposes. B) Human iPSCs cultured on top of human irradiated dermal fibroblasts grow as colonies with defined
borders.
As an option for culturing human PSCs without feeder cells, Matrigel™ has proven to be a
useful alternative enabling the stable culture of human PSCs. Moreover, we have also shown
that Matrigel™ allows the generation of hiPSCs without animal-derived feeder cells [19]. Since
Matrigel™ was derived from Engelbreth-Holm-Swarm mouse sarcoma cells [20], other types
of matrices which do not contain animal-derived agents have been tested and used as feeder-
cell substitutes for the successful maintenance and generation of human PSCs; such as CellStart
[21,22], recombinant proteins [23–25], and synthetic polymers [26,27].
The culture media used in the early generation of hESCs contained fetal bovine serum [1]. In
order to remove unspecific agents that might cause the differentiation of hESCs, knockout
serum replacement (KSR) has now been established as a defined material for maintaining
hESCs [28] and is also traditionally used for hiPSC generation [9,12,29,30]. In this regard,
mTeSR1 medium was developed as a chemically defined medium for maintaining human
PSCs [31]. Importantly, in the last years several authors have reported the generation of
commercially developed xeno-free media for maintaining hiPSCs, and such media have
already been used successfully for iPSCs generation. These media include: TeSR2 [32],
NutriStem [33], Essential E8 [24], and StemFit [34].
When factors that sustain PSCs stemness are deprived from the media, PSCs spontaneously
differentiate into derivatives of the three embryonic germ layers. This capacity has been
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profited for more than 30 years in order to direct PSCs to the desired cell product. In this regard,
up to day, an infinite number of protocols have been established to promote the development
of the cell type of interest.
The following are basic strategies to induce in vitro differentiation of PSCs cells:
a. Embryoid Bodies’ (EBs) formation: In contrast to monolayer cultures, EBs are spherical
structures that allow PSCs culture in suspension (Figure 3). The three-dimensional
structure, including the establishment of complex cell-adhesions and paracrine signaling
within the EB microenvironment, enables differentiation and morphogenesis. For that
reason, the first protocols for muscle differentiation took advantage of EB induction from
mESCs, followed by different periods of exposure to specific cell culture media in which
serum, mitogenic factors, and essential substrates (such as amino-acids or glutamine) were
formulated. In that manner, those first assays proved the feasibility of mESCs to give rise
to myogenic cells, setting the bases for the definition of robust protocols for the differen‐
tiation of muscle cells from human PSCs. Up to day, most of the protocols for the gener‐
ation of myogenic cells from PSCs make use of the differentiation of EBs derived from
either wild type or transgenic PSCs.
Figure 3. PSCs are capable to differentiate into cells belonging to the three somatic germ layers of the embryo. The
generation of EBs from PSCs is a common method for producing different cell lineages for further purposes. A) EBs
from mouse iPSCs grown in suspension. B) EBs derived from human iPSCs grown in suspension.
b. Modification of medium composition: Monolayers of PSCs and also EBs have been
traditionally subjected to changes in nutrient composition, (i.e, reduction/increase of
serum concentration, addition/removal of a growth factor or addition/removal of cyto‐
kines, among others) in order to induce their differentiation towards the desired cell type.
These changes are conducted in order to promote changes on gene expression profiles
and cell proliferation rates. In this manner, by means of relatively simple methods, PSCs
are artificially guided towards the desired cell type. Although these methodologies have
proven low efficiency yields for specific cell types (i.e., motorneurons, hepatic cells; among
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others), they are extremely valuable when combined together with PSCs in which the
expression of master factors critical for differentiation are under the control of hormones
(i.e., tamoxifen inducible reporters) or antibiotics (i.e., puromycin, or hygromycin, among
others). The control of expression of the specific transcription factor of choice (i.e., MyoD1)
together with the addition of specific molecules mimicking tissue development [i.e.,
insulin like growth factor 1 (IGF-1), basic fibroblast growth factor (bFGF)] has demon‐
strated good results when differentiating mouse or human PSCs towards myogenic cells.
c. Genetic manipulation of PSCs: Forced expression of transcription factors can direct
differentiation of PSCs toward specific lineages. In the last years, the generation of
platforms for transgene expression in PSCs has emerged as one of the most potent tools
for PSCs differentiation. Whereas the first studies took advantage of exogenous gene
expression systems (i.e., lentivirus or retrovirus), nowadays the use of integrative vectors
are limited, since they incur uncertain risks for potential cell-based therapeutic applica‐
tions [35]. In this regard, the use of excisable vectors (i.e., transposons; [36,37], or mRNAs
[17]) offer an unprecedented opportunity for the derivation of differentiated PSCs suitable
for regenerative medicine.
d. Use of extracellular matrix (ECM) and signaling molecules: Unlike de novo embryonic
muscle formation, muscle regeneration in higher vertebrates depends on the injured tissue
retaining of an ECM scaffolding that serves as a template for the formation of muscle fibers
[38]. In this regard, the interaction between cells and ECM via integrins determines the
expression of signaling molecules that affect PSCs differentiation [39]. Of note, when
mouse iPSCs have been cultured in the presence of matrigel, myogenesis (this is, prolif‐
eration of myoblasts and further fusion into myotubes) has been positively induced [40].
Similar results have been observed when using collagen-based matrix for the differentia‐
tion of human iPSCs expressing a Dox-inducible expression cassette of MyoD1 [41]. For
the organization and alignment of muscle fibers not only the composition of the ECM but
also its anisotropic architecture are essential. To address this, a number of strategies have
been developed to organize myotubes: topography-based approaches based on the use of
nanofibers, [42], microabrated surfaces [43], and microcontact printing of ECM proteins
such as fibronectin [44] and vitronectin [45]. In a complementary approach, biochemical
cues have also been introduced to promote cell alignment and differentiation. By using
inkjet bioprinting, spatially defined patterns of myogenic and osteogenic cells were
derived from primary muscle-derived stem cells (MDSCs) as a response to BMP-2
patterning [46]. The combination of topographical and biochemical signaling has also been
explored by coating sub-micron polystyrene fibers with either FGF-2 or BMP-2 to provide
spatial control of cell fate and alignment in order to mimic native tissue organization [47].
The vast majority of these works present cells to static microenvironments. Latest trends
point out the relevance of presenting cells to spatially and temporally dynamic microen‐
vironments [48]. Surfaces with gradient concentrations of growth factors (BMP-2 and
BMP-7) have shown to successfully drive cell differentiation [49,50]. Although not yet a
reality, these strategies appear a promising way to direct the differentiation of PSCs [51].
e. Use of biomatrices mimicking skeletal muscle niche: Tissue engineering approaches
have been used to design synthetic and natural 3D scaffold materials to mimic the
structural, biochemical, and mechanical properties of the stem cell niche [52,53]. Synthetic
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and natural scaffolds have been designed to provide support for muscle growth and allow
myofibroblasts to rebuild their native ECM. Natural scaffolds based on ECM proteins such
as fibrin and collagens have been used to form hydrogels for musculoskeletal tissue
engineering [54–56]. Commercially available ECM substitutes such as Matrigel™ hydro‐
gels are also showing promising results in the differentiation of PSCs towards cardio‐
myocytes [57]. However, current ECM protein-based scaffolds are limited by their
immune rejection and scaling up technologies. Synthetic scaffolds, which can be fabricated
with ideal architectures at the nanoscale, pore sizes and mechanical properties, represent
an advantageous solution to mimic the 3D ECM microenvironment (Figure 4). Technol‐
ogies such as electrospinning, which allows organizing the polymers into thin sheets of
fibrous meshes, are promising in this field [58,59]. Recently, it has been proved the
reprogramming of mouse fibroblasts onto cardiomyocyte-like cells on polyethylene glycol
(PEG) hydrogels functionalized with laminin and RGD peptides [60]. This opens new
perspectives toward the use of custom-engineered synthetic scaffolds in the differentia‐
tion of PSCs to muscle cells. Finally, the use of acellularized tissue scaffolds is also being
explored in muscle regeneration. They offer a native ECM with the optimal biochemical
and mechanical properties for cell culture and preserve the architectural features of the
tissue. Their use as a matrix supporting the commitment of cardiac muscle cells has been
recently reported, thus showing the potential of this approach [61].
Figure 4. Bio-inert polyethylene glycol (PEG)-based hydrogels have been designed as the scaffold substrate for biomi‐
metic matrices supporting muscle migration in three dimensions. The picture shows PEGDA hydrogel (MW 550 KDa)
cross-linked by UV light.
f. Co-culture with supportive cells (feeder cells): The co-culture of mouse and human PSCs
(either as monolayers or EBs) with feeder cells has been traditionally used in order to
induce PSCs differentiation [39]. The stromal cell line OP9 [62,63], which is derived from
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newborn mouse calvaria, supports hematogenesis [64,65]. The preadipose cell line PA6
[66] promotes neural differentiation of mouse and human PSCs [10,11,67]. In this regard,
Baghavati [68] showed that the co-culture of mESCs together with primary muscle cells
suffice for myogenic differentiation, since donor-derived myofibers generated by co-
culturing mouse EBs on top of primary muscle fibers could be occasionally found on the
surface of the host muscle.
3. Strategies to induce in vitro differentiation of mouse and human PSCs
towards myogenic cells
3.1. Generation of myogenic precursors and/or terminally differentiated multinucleated
myogenic cells by exogenous expression of transcription factors in PSCs
During the last 30 years successful generation of myogenic precursors from mouse and human
PSCs has been achieved by exogenous expression of transcription factors crucial for myogenic
differentiation. PSCs are especially amenable for genome editing because they can undergo
extensive tissue culture manipulations, such as drug selection and clonal expansion, while still
maintaining their pluripotency signature and genome stability. In his regard, different authors
have explored the possibility to generate PSCs stable cell lines that express the myogenic
transcription factor of interest under the control of specific drugs (i.e., antibiotics). The
myogenic transcription factor of interest is normally subcloned into a viral vector, which
possesses high infection efficiency when transducing PSCs. Other methods involve the use of
non-integrative vectors such as transposons or excisable lentiviral vectors. Following these
strategies different authors have shown that PSCs monolayers or PSCs-derived EBs can be
converted into myogenic cells (see below).
3.1.1. Early studies of myogenic differentiation from mESCs by exogenous expression of transcription
factors
Already in 1992 Dekel and colleagues showed that, when mESCs were electroporated with
MyoD1 cDNA driven by the Βeta-actin promoter, some cells could be converted to skeletal
muscle cells [69]. Moreover, authors showed that contracting skeletal muscle fibers could be
generated when the transfected cells were allowed to differentiate in vitro, via EBs, in low-
mitogen-containing medium. Although those studies failed to develop efficient protocols for
the generation of high yields of myogenic cells, they helped to understand that environmental
factors should control MyoD expression and its myogenic differentiation function, and more
importantly, that MyoD was required for the establishment of the myogenic program but not
for its maintenance.
Thus, those first observations served as a starting point for the definition of enriched cell
culture media for mESCs differentiation towards myogenic cells, and more importantly, for
the generation of fine-tuned systems in order to control the expression of the desired myogenic
factor at a precise moment during the onset of differentiation. Alongside this line, Ozasa and
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colleagues [70] established a mESC line by introducing a MyoD transgene controlled by a Tet-
Off system (ZHTc6-MyoD). The possibility to induce MyoD expression during the time course
of differentiation, allowed mESCs to differentiate almost exclusively into the myogenic lineage
in the absence of doxycycline, and without pre-differentiation into EBs. To start the differen‐
tiation process, Ozasa and colleagues removed doxycycline and used a differentiation medium
containing 4% fetal bovine serum (FBS). Under those conditions and only after 7 days, primed
cells started to fuse into myotubes, and occasionally light muscle contractions were observed.
In that study the potential of the generated cells to differentiate into myofibers in vivo was also
investigated by intramuscular injections into mdx mice and clusters of dystrophin-positive
myofibers were detected in the injected area.
3.1.2. Myogenic differentiation from human PSCs by exogenous expression of transcription factors
In the same manner, within the last years several studies have demonstrated the possibility to
generate myocytes, and even multinuclear myotubes from both hESCs and patient hiPSCs by
means of different systems in which the expression of MyoD is driven under the control of
soluble factors during the time course of differentiation. In this regard, early in 2012 two
different reports indicated that mesodermal [71] or mesenchymal cells [72] could be generated
from iPSCs, demonstrating a high potential for myogenic differentiation in response to MyoD
over-expression.
Also Rao and colleagues (2012) generated a transgenic Tet-inducible MyoD cassette in which
all the transgenic elements were inserted in hESCs making use of lentiviral vectors. In that
particular study, authors were able to generate multinucleated myotubes with 90% of effi‐
ciency in a period that lasted only 10 days. Later on, Yasuno and colleagues [37] improved a
previous protocol [36] for the generation of terminal multinucleated cells from iPSCs derived
from patients affected with Carnitine palmitoyltransferase II (CPT II). Their protocol consisted
in the transduction of a self-contained Tet-inducible MyoD1 expressing piggyBac vector (Tet-
MyoD1 vector) and transposase into hiPSCs by lipofection. This system allowed the indirect
monitoring of induced MyoD expression in response to doxycycline by co-expression of a red
fluorescent protein (mCherry). Moreover, in that particular setting authors increased the
purity of the generated myocytes by culturing the cells in low glucose conditions, a condition
that was also reported to increase differentiated cardiomyocytes out of undifferentiated iPSCs
based on the substantial biochemical differences in glucose and lactate metabolism between
differentiated cells and undifferentiated iPSCs [73].
Very recently, Abujarour and colleagues [41] found that it is possible to derive myotubes from
control iPSC and iPSC lines from patients with either Duchenne or Becker muscular dystro‐
phies. In particular, by using a lentiviral system expressing MyoD under the control of a Tet-
inducible promoter, and under-optimized culture conditions, the authors achieved an efficient
myogenic differentiation setting the bases for the production of scalable sources of normal and
dystrophic myoblasts for further use in disease modelling and drug discovery.
MyoD1 has not been the sole transcription factor of choice when differentiating human PSCs
towards myogenic cells. Iacovino and colleagues [74] generated an unprecedented system in
which it was possible to integrate the gene of interest into the desired cells (mESCs, kidney
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murine cells and hESCs) by means of a system that authors called inducible cassette exchange
(ICE). In that particular setting, authors were able to integrate one single copy of Myf5 into
mESCs and hESCs. Overall, Iacovino and colleagues showed that Myf5 expression is sufficient
to promote the myogenic commitment of nascent mesoderm thereby establishing a novel and
rapid method of differentiating mESCs and hESCs into skeletal muscle tissue.
Taking advantage of Iacovino´s system [74], Darabi and colleagues generated an improved
version of ICE system in order to generate mESCs in which Pax7 expression was controlled
under the control of doxycycline, and they succeeded in inducing the myogenic program in
mouse cultures [75,76]. Later on, the same authors generated inducible Pax7 hESCs and hiPSCs
with a doxycycline-inducible lentiviral vector encoding Pax7 (iPax7 and the expression of the
Pax 7 transgene was detected by incorporating an IRES-GFP reporter downstream of the Pax7
gene. Next, iPax7 hESCs and hiPSCs were induced to generate EBs and after three days
doxycycline was added into the media in order to induce Pax7 expression. Following 4 days
of induction, Pax7+GFP+ cells were purified by FACS and expanded in a secondary monolayer
culture in a medium containing doxycycline and bFGF. Under those conditions iPax7 hESCs
and hiPSCs expressed markers of early muscle differentiation (Pax7 and Pax3), and terminally
differentiated when iPax7 hESCs and iPSCs were subjected to differentiation-inducing
conditions (culture media with 5% horse serum and withdrawal of doxycycline and bFGF).
Finally, Darabi and colleagues demonstrated that transplantation of Pax7-derived myogenic
progenitors into dystrophin-deficient mice (mdx) promotes extensive and long-term muscle
regeneration accompanied by functional improvement [77].
3.2. Generation of myogenic precursors and/or terminally differentiated multinucleated
myogenic cells by soluble factors
Although in the last years different authors have shown the possibility to generate myogenic
cells from human PSCs by means of the ectopic expression of specific transcription factors,
these methods do not reflect normal development, and most importantly, are not suitable for
therapeutic purposes or in vitro disease modelling. For this reason, in the last years different
groups have investigated the possibility to expose EBs or monolayers of mouse and human
PSCs to different culture media mimicking muscle development. In order to monitor and
control the myogenic signature of the produced cells, authors have isolated the different
potential populations based on the acquisition of surface markers related to myogenic fate (i.e.,
paraxial mesoderm) by means of FACS. In the same manner, the majority of these studies have
relayed in the analysis of the expression of myogenic-related markers by common techniques
such as the expression of myogenic-related factors by polymerase chain reaction or immuno‐
histochemistry. In that way, the different protocols evaluate the efficiency of their method
quantifying the percentage of cells that are differentiated towards myogenic cells.
3.2.1. Early studies in myogenic differentiation from mESCs by soluble factors
Although EBs exposed to undefined differentiation cell culture media spontaneously develop
skeletal muscle cells and other cells in vitro, transplantation of EBs without any induction to
direct development along a specific pathway leads to a failure of integration into recipient
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tissues and often forms teratomas in transplanted tissues. Thus, the definition of the specific
conditions able to instruct PSCs towards myogenic cells requires establishment of robust
conditions able to guide cells through the different stages of muscle differentiation.
In the first moment authors thought that the co-culture of EBs on top of freshly isolated muscle
cells could serve as a novel method for myogenic differentiation. Although authors showed
that differentiated cells generated by this method developed vascularized and muscle tissue
when transplanted in dystrophic mice (mdx mice), still the number of engrafted cells was too
low for potential applications in a clinical setting [68]. Later, Zheng and colleagues [78] showed
that human EBs (hEBs) from two different hESCs lines cultured in the presence of differentia‐
tion media with different percentages of animal serum with or without Epidermal growth
factor and 5-azacytidine could give rise to myogenic precursors. Interestingly, in that same
work authors demonstrated that when those hESC-derived myogenic precursors were
transplanted in NOD-SCID mice they could incorporate into the host muscle efficiently and
become part of regenerating muscle fibers; giving rise to myocytes, myotubes, and myofibers,
as well as satellite cells.
3.2.2. Generation of myogenic cells from human PSCs by soluble factors
In the quest for protocols suitable for regenerative purposes, Barberi and colleagues [79,80]
developed simple feeder-free-monolayer culture systems in order to generate mesenchymal
precursors that could be further differentiated towards myogenic cells from hESCs. In those
studies multipotent mesenchymal precursors (MMPs) were purified for the acquisition of
CD73 surface marker using FACS technology. First, MMPs were maintained in inactivated
foetal serum and in the presence of the mouse skeletal myoblast line C2C12 [79]. Later, Barberi
and colleagues could avoid the use of C2C12 cells by using serum-free N2 medium. Moreover,
in that work authors further purified skeletal muscle myoblasts by means of a second FACS
analysis for the neural cell adhesion molecule (NCAM), a marker of embryonic skeletal muscle.
Those changes allowed for the expansion of hESC-derived myoblasts in a serum-free N2
medium in the presence of insulin [80].
Following a similar strategy Sakurai and colleagues [81] differentiated a murine ESC line
towards paraxial mesodermal progenitors. Specifically, authors selected paraxial mesodermal
progenitors based on the expression of platelet-derived growth factor receptor α (PDGFR-α)
and the absence of Flk-1–a lateral mesodermal marker. Later on, the same authors demon‐
strated that mESCs could be directed toward the paraxial mesodermal lineage by a combina‐
tion of bone morphogenetic protein (BMP) and Wnt signaling under chemically-defined
conditions [82]. Interestingly, the same group developed a protocol for the generation of
paraxial mesoderm progenitors from both miPSCs and hiPSCs. Although some differences in
growth factor requirement between mESCs and miPSCs cells were observed, the PDGFR-α+
population derived from miPSCs was almost identical to that of mESCs. Importantly, the work
of Sakurai and colleagues showed that, under their specific conditions, two different lines of
hiPSCs could be differentiated towards PDGFR-α+/KDR- cells. Those progenitors could be
further differentiated into osteocytes, chondrocytes, and skeletal muscle cells, demonstrating
the suitability of their procedures for the generation of myogenic cells for regenerative
purposes.
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Notably, other authors have shown the possibility to generate PDGFR-α+ from hESCs [83].
However, those same authors showed few engraftments of transplanted hESCs-derived
myogenic cells into injured skeletal muscle. Interestingly, the same authors have recently
demonstrated that, by incorporating Wnt3a in culture medium, myogenic commitment is
rapidly achieved from hESCs, and more significantly, that those cells can contribute to finally
regenerate cardiotoxin-injured skeletal muscle of NOD/SCID mice [84]. In the same line, other
authors have demonstrated that the inhibition of GSK3B and treatment with FGF2 could
specifically promote skeletal muscle differentiation. In particular, Xu and colleagues [85] have
demonstrated that simultaneous inhibition of GSK3B, activation of adenyl cyclase and
stimulation with FGF2 during EBs formation could promote the generation of myogenic
precursors that terminally differentiate in vitro and act as satellite cells upon transplantation.
Also, Borchin and colleagues [86] have shown that human PSCs can be differentiated towards
Pax3/Pax7 double positive cells after GSK3B and FGF2 exposure.
4. Induced pluripotent stem cells from patients: how to model muscle
disease in the Petri dish
The possibility to direct cell differentiation from human PSCs opens the door for the devel‐
opment of massive platforms for the study of muscle differentiation and disease progression.
Moreover, the possibility to combine gene-editing strategies allowing for the correction of the
genetic disorder leading to muscle disease, together with the generation of myogenic cells from
patients’ cells, represents an unprecedented opportunity for the establishment of in vitro
systems for the study of MDs.
So far, different groups have demonstrated the suitability of patient iPSCs approaches in order
to model MDs. Abujarour and colleagues [41] have derived myotubes from Duchenne
Muscular Distrophy (DMD) and Becker Muscular Distrophy (BMD) hiPSCs. In particular,
authors showed that myotubes derived from MDM and BMD iPSCs could respond to insulin-
like growth factor 1(IGF-1) and wingless-type MMTV integration site family member 7A
(Wnt7a) in a similar manner to primary myotubes. These results point out that iPSC derived
from MDM and BMD patients have no intrinsic barriers preventing from myogenesis, and
thus represent a scalable source of normal and dystrophic myoblast for further use in disease
modelling and drug discovery.
Recently, Tedesco and colleagues [71] generated iPSCs from fibroblasts and myoblasts from
limb-girdle muscular dystrophy 2D (LGMD2D) patients, developing the first protocol for the
derivation of mesoangioblast-like cells from these iPSCs. Moreover, authors expanded and
genetically corrected patient iPSC-derived mesoangioblasts in vitro by means of a lentiviral
vector for the expression of human α-sarcoglycan in striated muscle cells. When LGMD2D
disease free iPSC-derived mesoangioblasts were transplanted into α-sarcoglycan-null immu‐
nodeficient mice authors showed that they were capable to generate muscle fibers expressing
α-sarcoglycan. Interestingly, when the same experiments were conducted using mouse-
derived mesoangioblasts authors showed a functional amelioration of the dystrophic pheno‐
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type and restoration of the depleted progenitors in α-sarcoglycan-null immunodeficient mice.
Overall, Tedesco and colleagues showed that transplantation of genetically corrected meso‐
angioblast-like cells derived from iPSCs from LGMD2D patients could represent a novel
therapeutic approach for these patients.
In the same line, other authors [36] have generated iPSCs from patients affected by Miyoshi
myopathy (MM), a congenital distal myopathy caused by mutations in dysferlin. Specifically,
authors demonstrated that the expression of full-length dysferlin could restore the MM
associated phenotype in myotubes differentiated from MM-iPSCs. In the same line, Yasuno
and colleagues [87] have shown the possibility to generate iPSCs from patients affected by
Carnitine palmitoyltransferase II (CPT II) deficiency, an inherited disorder involving B-
oxidation of long-chain fatty acids (FAO).
Very recently, Li and colleagues [88] have demonstrated the possibility to correct iPSCs derived
from DMD patients by means of three different strategies: exon skipping, frameshifting, and
exon knock-in. In their hands, exon knock-in was the most effective approach. The work of Li
reveals the suitability of iPSC technology for the generation of iPSC-based approaches for MDs
modelling and therapy.
Overall, these recent advances set the bases for the generation of a previously nonexisting tool
for the study of MDs. The possibility to generate human models for the study of MDs by means
of iPSC technology opens the door for the development of novel therapeutic compounds for
MD treatment, and more importantly, to increase our understanding of MDs and muscle
development.
5. Protocols for the generation of patient-specific iPSCs
Within the last years, our group has participated in the development of protocols for the
derivation of patient iPSCs for disease modelling and compound screening. Taking advantage
of different basic techniques that are commonly used on a daily basis in any laboratory
worldwide, we have generated simple methodologies that allow the generation of patient-
specific iPSCs in a period that lasts only 50 days from the moment we get the primary samples
from patients (i.e., skin biopsy, lipoaspirates, etc.). In this section, we provide two concise
protocols for the derivation of patient iPSCs taking advantage of retroviruses and episomal
vectors.
5.1. Protocol for the generation of hiPSCs from keratinocytes derived from plucked hair
samples
The development of simple methods for the generation of hiPSCs from keratinocytes from
plucked hair samples offers an unprecedented scenario for the production of patient-specific
iPSCs, making use of a non-invasive procedure when collecting patient samples.
Our protocol is divided into three consecutive steps, which involve: A) Isolation of keratino‐
cytes from plucked hair samples, B) Production of retrovirus, and C) Infection of keratinocytes.
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The steps are detailed below. As described elsewhere, the same protocol can be applied when
reprogramming cord blood stem cells, kidney tubular epithelial cells, and dermal fibroblasts
[11,12,30].
a. Isolation of keratinocytes from plucked hair
A.1 The day before hair isolation coat the required number of 35-mm culture dishes with
Matrigel® (Becton Dickinson, S.A. cat. no. 356234) by adding 1 ml of Matrigel® and incubate
overnight at 4 ºC.
A.2 The same day of sample recovery, prepare a non-coated 100-mm bacterial plate containing
HBSS (Invitrogen cat. no. 14170-088) with 1% (vol/vol) Penicillin/Streptomycin (Invitrogen cat.
no. 15140-122).
A.3 After the patient reads and signs the informed consent use tweezers to gently pull the hair
out and place it on plates filled with HBSS medium. As recommended by Aasen and colleagues
[89] use hair from the occipital part of the head.
A.4 Making use of forceps submerge the hair in HBSS medium. Next, cut off the external part
of the hair leaving the bulb and outer root sheath.
A.5 As described by Aasen [89], at this stage two optional methodologies for growing kerati‐
nocytes from plucked hair are described: direct outgrowth and enzymatic digestion. In this
section, we are going to detail how to get direct outgrowths of keratinocytes from plucked
hair. For enzymatic digestion procedure follow Aasen recommendations [89].
A.6 Remove the plate from 4 ºC, aspirate the Matrigel® coating and rinse the plate with 2 ml
of hESCs medium: KO-DMEM (Invitrogen, cat. no. 10829-018), 20% KOSR (Invitrogen, cat. no.
10828-028), 10 ng ml-1 bFGF (Peprotech cat. No. 100-18B), 1 mM Glutamax (Invitrogen, cat.
no. 35050-038), 100 µM nonessential amino acids (Invitrogen, cat. no. 11140-050), 100 µM 2-
mercaptoethanol (Sigma, cat. no. M7522), and 50 U/ml (penicillin and 50 mg/ml streptomicin).
A.7 Place gently the hair obtained from the coated culture plates.
A.8 Add few drops of hESCs medium (0.3 mL) on top of the hair sample in order to keep the
hair humid. In the next 3–4 hours, add gently fresh hESCs medium (0.3 mL). The next day
carefully check under the microscope that the hair sample is still attached at the bottom of the
plate. Refill the plate with more hESCs medium on top of the hair, if necessary.
A.9 Add 1 ml of hESCs medium every following day. After 4 days, outgrowths of typical
epithelial keratinocytes are visible.
A.10 After 10–14 days, large colonies of keratinocytes (up to 1 cm of diameter) are visible. At
this stage, it is advisable to split the cells for infection or subculture to avoid cells to initiate
contact-dependent differentiation.
b. Production of retrovirus
B.1 Seed out 4.3x106 Phoenix Amphotropic 293 cells in 10 ml of DMEM complete medium
which consists in DMEM (Invitrogen, cat. no. 11965-092), 10% FBS (Invitrogen, cat. no.
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10270-106), Glutamax 2 mM, Penicillin/Streptomycin (100 U/ml, 100 µg/ml) in 100-mm culture
dishes and place in a 37 ºC 5% CO2 incubator.
B.2 Next day, prepare FuGENE:DNA complex according to the manufacturer´s instructions
(Roche Applied Science, cat. no. 1181509001). We recommend a ratio of 27 µl FuGENE to 9 µg
plasmid DNA for every 10 cm dish. For virus production, we will make use of pMSCV-based
plasmids. pMSCV-based retroviral vectors are commercially available for OCT4, SOX2, KLF4,
and c-Myc in Addgene (reference numbers are: 20072, 20073, 20074, and 20075 respectively).
If the infection efficiency wants to be monitored pMSCV-based retroviral vectors expressing
GFP can be used (Addgene plasmid 20672).
B.3 Add the FuGENE:DNA complex solution dropwise onto media (gently). Move the plate
carefully in order to distribute the transfection reaction homogenously.
B.4 Place the transfected cells at 37 ºC, with 5% CO2 overnight.
B.5 Next day, change DMEM complete medium gently (10 ml/plate) and incubate the plates
overnight at 32 ºC in a 5% CO2 incubator.
B.6 Collect viral supernatants and add fresh complete DMEM medium to the different plates.
Take care to avoid cells detaching from the tissue culture plates.
B.7 Every following day, for 2 days, repeat steps B.5 and B.6 in order to collect more viral
supernatants.
B.8 Filter the viral supernatant through a 0.45 µm PVDF filter (Millipore® SLHV033NK) to
remove any contaminant cells.
B.9 Add 1 µl polybrene (10 mg/ml; Chemicon cat. no. TR-1003-6) for each ml viral supernatant
needed (final polybrene concentration of 10 µg/ml).
c. Infection of keratinocytes derived from plucked hair samples
C.1 Wash obtained keratinocyte colonies growing from a hair in hESCs medium as described
in section (A) with PBS (Invitrogen, cat. no. 10010-056) and trypsinize them using 1 ml 0.25%
Trypsin/EDTA (Invitrogen, cat. no. 25200-056).
C.2 After 5–8 minutes, when cells are released from the plastic surface resuspend them with
10 ml hESCs medium.
C.3 Centrifuge at 200g for 5 min.
C.4 Resuspend the pellets in 4 ml of hESCs medium.
C.5 Plate cell suspensions in the desired wells of six-well plates (Corning, cat. no. 153516)
previously pre-coated with Matrigel® as explained in step A1. Seed 80.000 keratinocytes/well.
C.6 Next day add 1 ml of every single viral suspension obtained as described in steps B6-B9
for OCT4, SOX2, KLF4, and cMYC. Perform viral transduction in the same manner for GFP in
order to monitor the efficiency of viral infection.
C.7 Centrifuge plates at 650g for 45 min.
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C.8 Replace with 2 ml fresh hESCs medium (within 4–5 hours).
C.9 Next day, repeat steps C.7-C.8 to infect cells a second time.
C.10 Change media daily with hESCs medium.
C.11 After 1–2 weeks large colonies are visible and can be picked mechanically and transferred
onto irradiated human fibroblasts feeder layer (iHFF) and cultured as normal iPSCs following
specifications detailed before by others [12,29,30].
5.2. Protocol for the generation of hiPSCs from mesenchymal stem cells (MSCs) derived
from adipose tissue
The possibility to generate iPSCs by means of non-integrative strategies paves the way for the
development of clinical grade iPSCs from patients. Here, we detail a specific protocol for the
derivation of hiPSCs from mesenchymal stem cells from adipose tissue.
Our protocol makes use of commercial episomal plasmids generated by Okita and colleagues
[16]. Our method offers the possibility to generate patient-specific iPSCs in a period that last
only 20 to 22 days from the moment the reprogramming experiment starts.
a. Before nucleofection
A.1 Following the Human MSC Nucleofector® Kit (DPE-1001, Amaxa) recommendations the
solution for nucleofection is prepared by adding 0.5 ml of Supplement to 2.25 ml Nucleofector
Solution. Human MSC Nucleofector Solution is now ready to use and is stable for 3 months
at 4°C.
A.2 Under the culture hood prepare plasmid mixture by mixing 1 µg of each pCLXE episomal
based plasmid (i.e., if we want to reprogram three different samples 3 µg of each pCXLE
plasmid will be added to the final mixture). Plasmids are commercially available in Addgene:
pCXLE-hOCT3/4-shp53-F (Plasmid #27077), pCXLE-hSK (Plasmid #27078), pCXLE-hUL
(Plasmid #27080).
A.3 Pre-warm the complete Human MSC Nucleofector Solution to room temperature.
A.4 Pre-warm an aliquot mesenchymal stem cells culture medium [DMEM (Invitrogen, cat.
no. 11965-092), 10% FBS (Invitrogen, cat. no. 10270-106), Glutamax 2 mM, Penicillin/Strepto‐
mycin (100 U/ml, 100 µg/ml)] at 37 °C in a 50 ml tube (500 µl per sample; 1.5 ml for 3 samples).
A.5 Prepare 6-well plates by filling the appropriate number of wells with 1 ml of culture
medium containing mesenchymal stem cells culture medium and pre-incubate plates in a
humidified 37 °C/5% CO2 incubator. Prepare 2 wells/sample (i.e., 6 wells for 3 samples)
b. Nucleofection and iPSCs generation
B.1 Follow Human MSC Nucleofector® Kit recommendations (http://bio.lonza.com/filead‐
min/groups/marketing/Downloads/Protocols/Generated/Optimized_Protocol_90.pd).
B.2 After nucleofection transfer the nucleofected cells from the cuvettes using the plastic
pipettes provided by the kit to prevent damage and loss of cells distributing the total amount
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of cell suspensions into 2 wells containing the pre-warmed mesenchymal stem cells culture
medium. Incubate the cells in a humidified 37 °C/5% CO2 incubator.
B.3 After 4 days transfer, wash nucleofected samples with PBS (Invitrogen, cat. no.10010-056)
and trypsinize them using 1 ml 0.25% Trypsin/EDTA (Invitrogen, cat. no. 25200-056).
B.4 Transfer the nucleofected cells into six-well plates (Corning, cat. no. 153516) containing
irradiated murine fibroblasts (iMEF;C57BL/6 MEF 4M IRR; Global Stem) in hESCs medium:
KO-DMEM (Invitrogen, cat. no. 10829-018), 20% KOSR (Invitrogen, cat. no. 10828-028), 10 ng
ml-1 bFGF (Peprotech cat. No. 100-18B), 1 mM Glutamax (Invitrogen, cat. no. 35050-038), 100
µM nonessential amino acids (Invitrogen, cat. no. 11140-050), 100 µM 2-mercaptoethanol
(Sigma, cat. no. M7522), 50 U/ml (penicillin and 50 mg/ml streptomicin). Change hES media
every other day.
B.5 After 20 days, large colonies are visible and can be picked mechanically and transferred
onto iMEF and cultured as normal iPSCs following specifications detailed before by others
[12,29,30].
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